Location : Home > MEDIA

MEDIA

302023-03

Good news! SanReno officially joins the China Pharmaceutical Innovation and Research Development Association

Recently, the China Pharmaceutical Innovation and Research Development Association (hereinafter referred to “PhIRDA”) voted to approve the application for membership of SanReno Therapeutics (hereinafter referred to as "SanReno") at the 11th plenary meeting of the Council, and SanReno officially became a member of PhIRDA!

102023-01

BIG news！SanReno Global Scientific Advisory Board Established

Shanghai, China -- January 10, 2023 SanReno announced the formal establishment of the Scientific Advisory Board (SAB). As a fast growing biotech company , SanReno is committed to providing innovative treatments and game-changing clinical solutions in nephrology and related therapeutic areas. The Global Scientific Advisory Committee will enhance SanReno’s understanding of science, guide innovative R&D activities, and ensure streamlined corporate strategy.

292022-07

“Start Strong to Win For Kidney Patients”
The Kick Off Meeting of SanReno was successfully held in Shanghai

“Start Strong to Win for Kidney Patients” The SanReno Kick Off Meeting was successfully held on July 29 at the headquarter, Nan Fung Building, Shanghai.

032021-12

SanReno Therapeutics was Officially Established

SanReno Therapeutics is a joint venture focusing on nephrology and related therapeutic areas. Pivotal bioVenture Partners China jointly established SanReno in China together with Frazier Healthcare Partners, a well-known US life science fund, and Chinook Therapeutics, a clinical-stage biotechnology company. SanReno is led by pharmaceutical veterans from the top tier management team, such as Baxter, Novartis and etc. SanReno is committed to providing world-leading innovative treatments and clinical solutions to create better quality of life for more patients.

<1>

400-883-0816

info@sanreno.com

Shanghai ● Beijing, China

© 2022 SanReno. All Rights Reserved Terms of UsePrivacy Policy